Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 preliminary results include approximately $127 million pre-tax acquired IPR&D charge.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 preliminary results include approximately $127 million pre-tax acquired IPR&D charge
- GAAP and non-GAAP diluted EPS expected to decline approximately $1.00 from the charge
- Payments tied to collaboration and licensing agreements, including up-front and opt-in amounts
- Q2 results remain unaudited and subject to financial statement closing procedures
- Charge reflects transaction timing rather than core operating performance; investors should assess final disclosures separately
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.